Research & Development

Our people

Home / Our company / Our people / Research & Development

Jump to

At AstraZeneca, we focus on the discovery, 肿瘤学处方药的开发和商业化, BioPharmaceuticals and Rare Disease, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Our R&D groups are unified in their approach, 团结一致，为最需要的人提供改变生活的药物. By collaborating internally and externally, 澳门第一赌城在线娱乐的目标是加速发现新疗法，以满足未满足的医疗需求.

BioPharmaceuticals R&D

Adam Platt

转化科学和实验医学副总裁兼主管, Respiratory and Immunology, AstraZeneca
Amy Taylor

Business Planning & 运营总监，首席运营办公室，biopharmacticals R&D
Ben Challis

VP and Head of Translational Science & 实验医学，心血管，肾脏和代谢，澳门在线赌城娱乐

Oncology R&D

Alicyn Campbell

Head of Digital Health, Oncology R&D
Anas Younes

高级副总裁，血液学(早期和晚期)肿瘤学全球主管&D
Andrew Foxley

副总裁，特许经营主管，晚期肿瘤R&D

R&D

Alan Sabirsh

首席科学家，先进药物输送，制药科学，R&D
Anna Åsberg

Vice President, R&D IT
Annette Bak

高级药物输送主管，制药科学，R&D

Explore our people in other business units

Oncology
BioPharmaceutical
Rare Disease
Enabling Functions
Operations
International

Veeva ID: Z4-51286
Date of preparation: December 2022